로딩 중…
StockDiggingStockDigging

Eli Lilly and Company

LLY· NYSE
$1152.73+0.03%
2026-09-18

Financials

Valuation Metrics

Eli Lilly and Company's Market Cap is $1.09T. At end of 2025 it was $963.46B. Ranked #13 of 3,121 in US market (top 0.4%), #3 of 1,658 on NYSE (top 0.2%), #1 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.4%) by Market Cap.

Investment Metrics(as of 2026-09-18)

MetricValue
Size
Market Cap$1.09T
Revenue$79.67B
Net Income$26.71B
Total Assets$142.28B
Net Assets$33.88B
Employees50,000
Value
P/E40.63x
P/B32.03x
PEG0.43x
P/S13.62x
EV/EBITDA32.13x
FCF Yield1.85%
Profitability
ROE78.84%
ROA18.77%
Op. Margin43.92%
Revenue Growth49.58%
Earnings Growth93.55%
Financial Health
Debt Ratio319.97%
Total Debt$54.91B
FCF$20.05B
Cash$8.89B
Current Ratio1.35x
Net Debt/EBITDA1.31x
Dividend
Div. Yield0.53%
Div. Growth15.36%
Performance
1Y Return51.57%
1M Return-9.97%
From 52W High-10.82%
1Y MDD-23.18%
Trading
Volume1,826,677 shares
Trading Value$2.10B
Per Share
EPS$28.37
BPS$35.99

Company Info

CEO Mr. David A. Ricks
Employees 50,000
HQ Indianapolis, United States

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.